Press Releases.

Month Year

Month Year

Investor Alerts

July 30, 2014

Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call
July 21, 2014

Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
June 25, 2014

Regulus Announces Patent Grant from U.S. Patent Office in Sarnow Patent Estate on microRNA Therapeutics for the Treatment of HCV

- New Method of Use Claims Strengthen Patent Estate Covering microRNA-122 Inhibitors for the Treatment of HCV Infection -
June 16, 2014

Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer

- Recognized Industry Leader Brings Extensive Clinical and Product Development Expertise -
- Photos 1
May 09, 2014

Regulus to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference

Show per page